

BAXTER INTERNATIONAL INC.
SCHEDULE III
Consolidated Statements of Income
Restatement of Prior Quarters
Discontinued Operations Only
(unaudited)
(in millions, except per share data)
(per share data restated for two-for-one stock split)

	Q1	Q2	2001 Q3	Q4
NET SALES:				
BIOSCIENCE	\$--	\$--	\$--	\$--
MEDICATION DELIVERY	6	7	8	9
RENAL	62	67	83	65
TOTAL NET SALES	68	74	91	74
GROSS PROFIT	3	5	8	8
% to Sales	4.4%	6.8%	8.8%	10.8%
MARKETING AND ADMINISTRATIVE EXPENSES	6	7	7	9
% to Sales	8.8%	9.5%	7.7%	12.2%
RESEARCH AND DEVELOPMENT EXPENSES	--	--	1	--
GOODWILL AMORTIZATION	1	1	1	1
OPERATING INCOME	(4)	(3)	(1)	(2)
% to Sales	(5.9%)	(4.1%)	(1.1%)	(2.7%)
INTEREST, NET	1	--	--	--
OTHER EXPENSE	1	--	1	2
INCOME BEFORE INCOME TAXES	(6)	(3)	(2)	(4)
INCOME TAX EXPENSE	(2)	(1)	--	(1)
NET INCOME	(\$4)	(\$2)	(\$2)	(\$3)
BASIC EPS	(\$0.01)	(\$0.01)	\$0.00	(\$0.01)
DILUTED EPS	(\$0.01)	(\$0.01)	\$0.00	(\$0.01)

	Q1	2002 Q2	Q3
NET SALES:			
BIOSCIENCE	\$--	\$--	\$--
MEDICATION DELIVERY	11	12	12
RENAL	64	65	61
TOTAL NET SALES	75	77	73
GROSS PROFIT	6	7	6
% to Sales	8.0%	9.1%	8.2%
MARKETING AND ADMINISTRATIVE EXPENSES	7	10	8
% to Sales	9.3%	13.0%	11.0%
RESEARCH AND DEVELOPMENT EXPENSES	--	--	1
GOODWILL AMORTIZATION	--	--	--
OPERATING INCOME	(1)	(3)	(3)
% to Sales	(1.3%)	(3.9%)	(4.1%)
INTEREST, NET	--	--	--
OTHER EXPENSE	1	2	--
INCOME BEFORE INCOME TAXES	(2)	(5)	(3)
INCOME TAX EXPENSE	(2)	(1)	(2)
NET INCOME	\$--	(\$4)	(\$1)
BASIC EPS	\$0.00	(\$0.01)	\$0.00
DILUTED EPS	\$0.00	(\$0.01)	\$0.00